Premium
Monodose versus 3 daily doses of sodium valproate: a controlled trial
Author(s) -
Gjerløff Iben,
Arentsen Jens,
Alving Jørgen,
Secher Birgitte G.
Publication year - 1984
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1984.tb07788.x
Subject(s) - anticonvulsant , epilepsy , valproic acid , medicine , anesthesia , clinical trial , psychiatry
— 12 patients with absence epilepsy were treated with alternatively 1 or 3 daily doses of sodium valproate (VPA) in a double‐blind cross‐over design. Seizure frequency, EEG paroxysmal activity, clinical side‐effects and laboratory findings were assessed for both treatment periods. There was no statistically significant difference between the 2 dosage schedules, and the simplicity of monodose treatment is an important factor in good patient compliance. The apparent discrepancy between plasma half‐life and biological action of VPA is discussed.